Keywords: Algeta, Bayer, Radium-223, Alpparadin, USA, FDA, Priority review, Prostate cancer
FDA priority review for Algeta and Bayer's prostate cancer agent radium-223
Article | 14 February 2013
German pharma major Bayer (BAYN: DE) has received notification from the US Food and Drug Administration granting priority review of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
